Drugs / GBP560-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06680128 | Feb 2025 → Jul 2026 | Japanese encephalitis | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBP560-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680128 ↗ |
| Modality | Messenger RNA (mRNA) | “SK Japanese Encephalitis mRNA vaccines (GBP560)” NCT06680128 ↗ |
| Route | Intramuscular | “Participants will receive 2 intramuscular injections of the test vaccines in stage 2.” NCT06680128 ↗ |